Mercury Therapeutics Licenses Dartmouth Protein Kinase IP to Millipore | GenomeWeb

NEW YORK (GenomeWeb News) - Mercury Therapeutics said yesterday that it has granted Millipore exclusive worldwide rights to human AMP-activated protein kinase in the field of research products and services.

The AMPK patent was originally licensed by Mercury Therapeutics in 2000 from Dartmouth College. The patent is based on research by Dartmouth professor Lee Witters and his collaborator Bruce Kemp from the St. Vincent's Institute for Medical Research in Melbourne, Australia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.